Empagliflozin was found to be associated with a lower combined risk for cardiovascular death or hospitalization for heart failure compared with placebo in patients receiving recommended therapy for heart failure.
An abridged version of the REVEAL risk calculator, the REVEAL Lite 2, represents a simpler and accurate tool for predicting mortality risk in patients with pulmonary arterial hypertension.
Quality of care and in-hospital mortality were found to be comparable for patients with heart failure who were covered by Medicare Advantage or fee-for-service Medicare.
In a European study, approximately one-third of hospitalizations involving patients with recurrent hyperkalemia directly related to serum potassium elevation.
Supplementation with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is associated with a reduced risk for myocardial infarction (MI) and coronary heart disease (CHD) events.
Researchers evaluated the prevalence of abdominal aortic calcification and its association with prevalent vertebral fractures in women with rheumatoid arthritis.
Researchers evaluated the association between osteoporosis and vertebral fragility fractures with cardiovascular calcification in patients with chronic obstructive pulmonary disease.
Coronary microvascular dysfunction was found to be independently associated with hospitalization for heart failure and cardiovascular death in patients with chronic stable HFpEF.
Oral combination therapy does not appear to help achieve or maintain low risk status in most treatment-naive patients with pulmonary arterial hypertension.
Higher doses of renin angiotensin system blockade were found to be associated with improved survival and beneficial left ventricular remodeling 3 years after transcatheter aortic valve replacement.
Multichannel smartwatch ECG were found to be in agreement with standard ECGs for the detection of ST-segment changes in patients with acute coronary syndrome.
